Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label Extension

Publication Details

Circulation

November 2026

Access Here

Author(s)

Pablo Garcia-Pavia¹, Ronald Witteles², Caroline Morbach³, Diego Delgado⁴, Hiroaki Kitaoka⁵, Mathew S Maurer⁶, Peter van der Meer⁷, Ali Yilmaz⁸, Vincent Algalarrondo⁹, Scott D Solomon¹⁰, Francesco Cappelli¹¹, Olga Azevedo¹², W H Wilson Tang¹³, Olivier Lairez¹⁴, Katherine L Boyle¹⁵, Satish A Eraly¹⁵, Yinggu Bao¹⁵, Shaun Bender¹⁵, John Vest¹⁵, Marianna Fontana¹⁶

Affiliations

¹Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Majadahonda and Madrid, Spain (P.-G.P.); ²Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (R.W.); ³Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital Würzburg, Germany (C.M.); ⁴University Health Network of Toronto, Canada (D.D.); ⁵Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Japan (H.K.); ⁶Columbia University Irving Medical Center, New York, NY (M.S.M.); ⁷University Medical Center Groningen, University of Groningen, the Netherlands (P.v.M.); ⁸Division of Cardiovascular Imaging, University Hospital Münster, Germany (A.Y.); ⁹Department of Cardiology, French Reference Center for Cardiac Amyloidosis CERAMIC, Bichat University Hospital, AP-HP, Paris, France (V.A.); ¹⁰Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.D.S.); ¹¹Tuscan Regional Amyloidosis Centre, Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy (F.C.); ¹²Cardiology Department, Hospital da Senhora da Oliveira, Guimarães, Portugal (O.A.); ¹³Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH (W.H.W.T.); ¹⁴Department of Cardiology, Health Age Institute, Toulouse University Hospital, University of Toulouse, France (O.L.); ¹⁵Alnylam Pharmaceuticals, Cambridge, MA (K.L.B., S.A.E., Y.B., S.B., J.V.); ¹⁶Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, UK (M.F.)

Abstract

Background

In HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular events and slowed disease progression measures versus placebo in patients with TTR (transthyretin) amyloidosis with cardiomyopathy after 33 to 36 months. We report the long-term efficacy and safety of vutrisiran from an ongoing open-label extension of HELIOS-B.

Methods

Patients who completed HELIOS-B could enroll in the open-label extension, continuing with vutrisiran 25 mg every 3 months (continuous vutrisiran) or, if previously receiving placebo, initiating vutrisiran 25 mg every 3 months (placebo/vutrisiran). Prespecified end points assessed in the open-label extension are the composite of ACM and cardiovascular events, ACM, Kansas City Cardiomyopathy Questionnaire–Overall Summary score, New York Heart Association class, and NT-proBNP (N-terminal pro–B-type natriuretic peptide) and troponin I levels. Outcomes were assessed through month 48 in this analysis.

Results

Of 654 participants in HELIOS-B (vutrisiran, n=326; placebo, n=328), 478 completed double-blind treatment and 466 (vutrisiran, n=243; placebo, n=223) entered the open-label extension. In the continuous vutrisiran group, the risk of first cardiovascular event or ACM was reduced by 37% (hazard ratio, 0.63 [95% CI, 0.51, 0.79]; P=0.0001) and ACM by 37% (hazard ratio, 0.63 [95% CI, 0.46, 0.84]; P=0.0023) versus the placebo/vutrisiran group. Through month 48, patients in the continuous vutrisiran group had preserved health status and quality of life per Kansas City Cardiomyopathy Questionnaire–Overall Summary score (least squares mean difference, 9.0 [95% CI, 5.3, 12.6]; P<0.0001) and more patients had improved or stable New York Heart Association class (odds ratio, 1.6 [95% CI, 1.1, 2.2]; P=0.0084) versus the placebo/vutrisiran group. Benefits in the continuous vutrisiran group were maintained for NT-proBNP and troponin I levels (adjusted geometric mean fold change ratios, 0.66 [95% CI, 0.58, 0.74]; P<0.0001; and 0.71 [95% CI, 0.64, 0.79]; P<0.0001, respectively) versus the placebo/vutrisiran group. Similar benefits were observed in the vutrisiran monotherapy population. No new safety signals were observed.

Conclusions

Long-term vutrisiran resulted in clinically meaningful benefits across mortality, cardiovascular events, cardiac biomarkers, functional status, and quality of life in patients with TTR amyloidosis with cardiomyopathy through month 48. Patients initially treated with vutrisiran had better outcomes than those first receiving placebo, highlighting the importance of early diagnosis and treatment in TTR amyloidosis with cardiomyopathy.